bluebird bio Inc - Company Profile
Powered by 
All the data and insights you need on bluebird bio Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date bluebird bio Inc Strategy Report
- Understand bluebird bio Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
bluebird bio Inc (bluebird bio) is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD); betibeglogene autotemcel for transfusion-dependent beta thalassemia; Lovo-cel for the treatment of sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with pharmaceutical companies to discover, develop and commercialize gene therapy products. bluebird bio is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
455 Grand Union Boulevard, Somerville, Massachusetts, 02145
Website
www.bluebirdbio.com
Telephone
1 339 4999300
No of Employees
323
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BLUE (NASD)
Revenue (2021)
$3.6M
-1.8%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
67.5%
(2021 vs 2020)
Market Cap*
$188.5M
Net Profit Margin (2022)
XYZ
66.9%
(2021 vs 2020)
* As of and is in US$
bluebird bio Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Zynteglo (betibeglogene autotemcel) - beta Thalassemia | Lenti-D |
| Abecma (idecabtagene vicleucel) – Relapsed/Refractory Multiple Myeloma | Zynteglo |
| Pipeline | LentiGlobin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company entered into a US$175 million term loan facility with Hercules Capital Inc. |
| 2023 | Contracts/Agreements | In October, the company entered into an agreement to sell a rare pediatric disease priority review voucher. |
| 2022 | Regulatory Approval | In September, the company secured accelerated approval from the US FDA for SKYSONA for active cerebral adrenoleukodystrophy. |
Competitor Comparison
| Key Parameters | bluebird bio Inc | Beam Therapeutics Inc | Global Blood Therapeutics Inc | Sangamo Therapeutics Inc | Intellia Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Somerville | Cambridge | South San Francisco | Richmond | Cambridge |
| State/Province | Massachusetts | Massachusetts | California | California | Massachusetts |
| No. of Employees | 323 | 436 | 457 | 405 | 526 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Andrew Obenshain | President; Chief Executive Officer; Director | Executive Board | 2021 | 49 |
| Christopher Krawtschuk | Chief Financial Officer | Senior Management | 2022 | 49 |
| Thomas J. Klima | Chief Operating Officer; Chief Commercial Officer | Senior Management | 2021 | 51 |
| Richard A. Colvin, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2021 | 57 |
| Joseph Vittiglio | Chief Business and Legal Officer | Senior Management | 2023 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward